See more : TOA Corporation (6809.T) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunoGen, Inc. (IMGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunoGen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- abrdn Global Income Fund, Inc. (FCO) Income Statement Analysis – Financial Results
- Smart Closet Inc. (ZSYC) Income Statement Analysis – Financial Results
- Aryaman Financial Services Limited (ARYAMAN.BO) Income Statement Analysis – Financial Results
- InterPrivate II Acquisition Corp. (IPVA-UN) Income Statement Analysis – Financial Results
- Foresight Acquisition Corp. (FORE) Income Statement Analysis – Financial Results
ImmunoGen, Inc. (IMGN)
About ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.78M | 108.78M | 132.30M | 82.27M | 53.82M | 115.45M | 48.63M | 60.00M | 85.54M | 59.90M | 35.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 38.21M | 32.09M | 35.72M | 25.96M | 7.63M | 5.88M | 4.48M | 11.18M | 3.70M | 600.00K | 400.00K | 500.00K | 500.00K | 900.00K | 1.70M | 2.70M | 3.40M | 1.00M | 800.00K |
| Cost of Revenue | 176.00K | 176.00K | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.57M | 2.67M | 9.24M | 5.66M | 2.83M | 3.34M | 597.05K | -463.45K | -500.00K | -1.10M | -1.50M | -6.00M | 13.40M | 17.90M | -1.70M | -1.30M | 9.50M | 7.10M | 4.70M |
| Gross Profit | 108.61M | 108.61M | 17.71M | -32.25M | -120.07M | -24.29M | -92.68M | -86.91M | -26.23M | -47.06M | -51.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 34.64M | 29.42M | 26.48M | 20.30M | 4.79M | 2.54M | 3.88M | 11.64M | 4.20M | 1.70M | 1.90M | 6.50M | -12.90M | -17.00M | 3.40M | 4.00M | -6.10M | -6.10M | -3.90M |
| Gross Profit Ratio | 99.84% | 99.84% | 13.38% | -39.20% | -223.11% | -21.04% | -190.60% | -144.85% | -30.66% | -78.57% | -145.03% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 90.65% | 91.69% | 74.14% | 78.20% | 62.84% | 43.21% | 86.67% | 104.15% | 113.51% | 283.33% | 475.00% | 1,300.00% | -2,580.00% | -1,888.89% | 200.00% | 148.15% | -179.41% | -610.00% | -487.50% |
| Research & Development | 213.37M | 213.37M | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 69.19M | 63.45M | 50.28M | 45.90M | 60.01M | 45.84M | 40.91M | 30.54M | 22.22M | 23.43M | 17.69M | 15.21M | 8.88M | 6.10M | 6.60M | 7.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 43.81M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 72.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.13M | 116.13M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 4.48M | 3.06M | 1.80M | 1.70M | 2.20M | 1.80M | 3.00M | 4.50M | 20.20M | 18.00M | 1.40M | 1.40M | 1.00M |
| Other Expenses | 3.35M | 3.35M | 1.21M | 5.01M | 3.33M | 2.61M | 0.00 | 304.00K | -848.00K | 167.00K | 198.00K | 64.68M | 56.20M | 44.92M | 38.34M | 44.98M | 23.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| Operating Expenses | 329.50M | 329.50M | 153.19M | 153.01M | 210.60M | 173.65M | 43.54M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 56.87M | 50.81M | 39.30M | 28.86M | 29.39M | 23.10M | 19.69M | 12.40M | 8.40M | 9.40M | 11.10M | 17.40M | 6.40M | 6.50M | 21.90M | 19.30M | 2.50M | 2.10M | 1.30M |
| Cost & Expenses | 329.68M | 329.68M | 153.19M | 153.01M | 210.60M | 173.65M | 184.85M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 60.44M | 53.47M | 48.54M | 34.51M | 32.22M | 26.44M | 20.29M | 11.94M | 7.90M | 8.30M | 9.60M | 11.40M | 19.80M | 24.40M | 20.20M | 18.00M | 12.00M | 9.20M | 6.00M |
| Interest Income | 4.34M | 51.00K | 729.00K | 4.42M | 0.00 | 0.00 | 20.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 4.17M | 23.20M | 16.97M | 10.73M | 16.72M | 0.00 | 20.13M | 5.44M | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 221.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.35M | -1.08M | 115.80M | 26.45M | 7.41M | 5.96M | 6.01M | 5.33M | 5.51M | 4.60M | 4.64M | 4.63M | 4.94M | 4.84M | 5.00M | 3.93M | 3.15M | 2.69M | 2.22M | 1.29M | 1.13M | 984.76K | 612.82K | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| EBITDA | -217.55M | -217.55M | -19.68M | -65.73M | -153.45M | -55.60M | -125.20M | -123.53M | -55.30M | -71.53M | -73.01M | -73.20M | -62.10M | -51.29M | -31.60M | -32.30M | -22.35M | -18.99M | -10.53M | -8.59M | -25.42M | -20.57M | -15.66M | -366.61K | -3.80M | -6.60M | -7.90M | -3.00M | -15.90M | -21.50M | -16.80M | -14.00M | -7.50M | -7.50M | -4.90M |
| EBITDA Ratio | -199.98% | -199.98% | -14.88% | -79.89% | -285.15% | -48.16% | -257.46% | -205.87% | -64.65% | -119.43% | -205.46% | -447.48% | -321.69% | -367.88% | -112.89% | -80.25% | -58.48% | -59.19% | -29.47% | -33.09% | -333.30% | -349.63% | -349.69% | -3.28% | -102.70% | -1,100.00% | -1,975.00% | -600.00% | -3,180.00% | -2,388.89% | -988.24% | -518.52% | -220.59% | -750.00% | -612.50% |
| Operating Income | -220.89M | -220.89M | -135.49M | -92.17M | -160.48M | -58.98M | -131.21M | -123.83M | -54.46M | -71.53M | -73.01M | -73.26M | -60.19M | -51.24M | -31.82M | -34.11M | -22.23M | -21.39M | -12.82M | -8.56M | -24.59M | -20.56M | -15.81M | -761.00K | -4.20M | -7.70M | -9.20M | -10.90M | -19.30M | -23.50M | -18.50M | -15.30M | -8.60M | -8.20M | -5.20M |
| Operating Income Ratio | -203.06% | -203.06% | -102.41% | -112.04% | -298.20% | -51.09% | -269.83% | -206.37% | -63.66% | -119.43% | -205.46% | -447.86% | -311.77% | -367.46% | -113.68% | -84.75% | -58.16% | -66.65% | -35.90% | -32.97% | -322.39% | -349.41% | -353.01% | -6.81% | -113.51% | -1,283.33% | -2,300.00% | -2,180.00% | -3,860.00% | -2,611.11% | -1,088.24% | -566.67% | -252.94% | -820.00% | -650.00% |
| Total Other Income/Expenses | -818.00K | -14.23M | -21.99M | -11.96M | -8.36M | -37.03M | -25.52M | -19.83M | -6.28M | 167.00K | 198.00K | -62.00K | 1.91M | 58.00K | -221.00K | 2.12M | 3.27M | 3.57M | 1.90M | 2.69M | 4.65M | 6.05M | 6.34M | 523.44K | 100.00K | 100.00K | 200.00K | -5.60M | -600.00K | -200.00K | -100.00K | 0.00 | -100.00K | -100.00K | -100.00K |
| Income Before Tax | -221.71M | -221.71M | -44.37M | -104.13M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -51.18M | -32.04M | -31.99M | -18.95M | -17.82M | -10.92M | -5.87M | -19.95M | -14.50M | -9.47M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.70M | -8.30M | -5.30M |
| Income Before Tax Ratio | -203.81% | -203.81% | -33.54% | -126.57% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -367.04% | -114.47% | -79.49% | -49.60% | -55.53% | -30.58% | -22.62% | -261.49% | -246.51% | -211.49% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -255.88% | -830.00% | -662.50% |
| Income Tax Expense | 1.22M | 1.22M | 22.31M | 17.96M | 7.39M | 37.03M | 0.00 | 19.83M | 6.28M | -167.00K | -198.00K | 62.00K | -1.91M | -265.00K | -100.00K | 27.00K | 35.00K | 17.00K | 29.00K | 45.49K | 35.13K | 127.81K | 82.60K | 237.56K | 4.10M | 7.60M | 9.00M | 16.50M | 19.90M | 23.70M | 18.60M | 15.30M | 100.00K | 8.30M | 5.30M |
| Net Income | -222.93M | -222.93M | -66.68M | -122.09M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -50.91M | -31.94M | -32.02M | -18.99M | -17.83M | -10.95M | -5.92M | -19.98M | -14.63M | -15.29M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.80M | -8.30M | -5.30M |
| Net Income Ratio | -204.93% | -204.93% | -50.40% | -148.40% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -365.14% | -114.11% | -79.55% | -49.69% | -55.58% | -30.66% | -22.80% | -261.95% | -248.68% | -341.36% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -258.82% | -830.00% | -662.50% |
| EPS | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| EPS Diluted | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| Weighted Avg Shares Out | 253.33M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 29.52M | 25.53M | 24.21M | 17.86M | 12.50M | 12.57M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
| Weighted Avg Shares Out (Dil) | 253.63M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 32.85M | 25.53M | 24.21M | 17.86M | 12.50M | 12.62M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Analyzing The Acquisition Potential Of ImmunoGen
ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European pharma companies, including GSK, Sanofi, or Merck, may be interested in ImmunoGen. ImmunoGen has an approved drug, a modest...
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for mirvetuximab soravtansine (ELAHERE®)...
ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?
ImmunoGen (IMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Top Medical Stocks to Buy Amid Recent Market Volatility
Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.
New Strong Buy Stocks for October 20th
OSCR, IMGN, AFRM, ACVA and SOLO have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2023.
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results.
3 Solid Stocks to Buy for Superb Earnings Acceleration
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.
New Strong Buy Stocks for October 18th
MRO, APA, IMGN, RAIL and MFA have been added to the Zacks Rank #1 (Strong Buy) List on October 18, 2023.
Source: https://incomestatements.info
Category: Stock Reports